Targeting Specific Metabolic Compounds
Allena is developing non-absorbed oral enzymes that target toxic metabolites, including oxalate and uric acid. Because Allena products are formulated to be non-absorbed, they act locally in the gastrointestinal tract, and then are eliminated as waste through normal digestion.
Off-target effects are minimized because of the high degree of enzyme specificity.
The company’s lead product candidate, ALLN-177, is in clinical testing for the treatment of adult secondary hyperoxaluria, and a program is being planned to address the orphan designation of pediatric hyperoxaluria. The company's second candidate, ALLN-346, is in early stage R&D for hyperuricemia.